Neuromersiv
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Neuromersiv is an Australian digital health company building immersive virtual reality solutions for neurorehabilitation. Its flagship product, Ulysses, is a VR-based upper-limb therapy system — registered as a medical device with Australia's TGA and the UK's MHRA — that helps stroke, spinal cord, and acquired brain injury survivors regain independence through clinically validated, task-specific training in immersive VR designed to drive neuroplasticity. Founded in late 2017 by Anshul Dayal, Oliver Morton-Evans, and Rohan O'Reilly, it raised pre-seed funding from Artesian and MedTech Actuator alongside government grants, and built partnerships with rehabilitation providers, hospitals, and universities in Australia, India, and Taiwan.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Anshul Dayal, Oliver Morton-Evans, and Rohan O'Reilly co-founded Neuromersiv in late 2017, moving through accelerator programs including muru-D, Cicada Medlab, and MedTech Actuator.
- Grants and clinical progress
The company secured government grants including ~$994K from MTPConnect and $231K from Accelerating Commercialisation, and completed a phase 1 clinical trial of Ulysses in Australia.
- Partnerships and adoption
Neuromersiv partnered with UK rehab provider Askham and Australian rehabilitation networks; the Australian government adopted the Ulysses system for traumatic brain injury treatment programs.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.